Free Trial

Scienture Q1 2023 Earnings Report

Scienture logo
$1.55 -0.10 (-6.06%)
As of 03/28/2025 04:00 PM Eastern

Scienture EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Scienture Revenue Results

Actual Revenue
$2.25 million
Expected Revenue
$2.47 million
Beat/Miss
Missed by -$220.00 thousand
YoY Revenue Growth
N/A

Scienture Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Scienture Earnings Headlines

Scienture appoints Rath as CCO, enters agreement with Syneos
This trading frustration almost made me quit
This happened to me time and time again, and I wanted no more of it. That’s exactly why I set out to refine my strategy… And with the help of my good friend Nate, we have done exactly that… Now, I cannot promise future returns or against losses, but the real trades so far have been nothing but astounding. Turning my once 69% win rate, into 83.3% on real trades in the last two months. And instead of just telling you, I want to SHOW you.
Scienture announces draaw on Equity Line of Credit
Scienture announces U.S. FDA approval of NDA for SCN-102
See More Scienture Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scienture? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scienture and other key companies, straight to your email.

About Scienture

Scienture (NASDAQ:SCNX) engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

View Scienture Profile

More Earnings Resources from MarketBeat